Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 12/02 11:18:55 am
7950 GBX   +1.92%
11:18aWho, when and how? A look at the UK's vaccination rollout
AQ
11:05aHow the U.K. Beat the U.S. and Europe to a Covid-19 Vaccine
DJ
09:29aASTRAZENECA : Crestor to be divested to Grunenthal in Europe
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at GBX 7690 GBX in weekly data.
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the GBX 7748 support.
  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 39% by 2022.
  • The group's high margin levels account for strong profits.
  • Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 7690 GBX
Weaknesses
  • The company's enterprise value to sales, at 4.36 times its current sales, is high.
  • The firm trades with high earnings multiples: 32.79 times its 2020 earnings per share.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ASTRAZENECA PLC2.54%137 451
JOHNSON & JOHNSON1.08%388 168
ROCHE HOLDING AG-4.59%284 650
PFIZER, INC.6.17%219 056
MERCK & CO., INC.-10.34%206 324
NOVARTIS AG-11.46%205 415
ABBVIE INC.17.51%183 680
NOVO NORDISK A/S7.85%156 152
BRISTOL-MYERS SQUIBB COMPAN..-2.77%141 031
ELI LILLY AND COMPANY10.75%131 962
AMGEN INC.-6.63%131 035
SANOFI-6.16%127 364
GLAXOSMITHKLINE PLC-22.37%92 309
CHUGAI PHARMACEUTICAL CO., ..49.08%78 894
JIANGSU HENGRUI MEDICINE CO..20.12%70 444
DAIICHI SANKYO COMPANY, LIM..52.32%68 197
More Results
Financials (USD)
Sales 2020 26 494 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 44,0x
Yield 2020 2,69%
Capitalization 137 B 137 B -
EV / Sales 2020 5,68x
EV / Sales 2021 4,95x
Nbr of Employees 70 600
Free-Float 95,7%
Upcoming event on ASTRAZENECA PLC
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes